scholarly journals HEMODYNAMICS IN THE BRANCHES OF THE AORTIC ARCHIN CHRONIC LIVER DISEASES

2015 ◽  
Vol 7 (1) ◽  
pp. 64-67
Author(s):  
V E Kulikov ◽  
T A Emelina ◽  
V A Kornilova ◽  
M A Toneva ◽  
E R Antonova
Keyword(s):  
Blood Flow ◽  
Hepatic Encephalopathy ◽  
Vascular Resistance ◽  
Liver Diseases ◽  
Hemispheric Asymmetry ◽  
Positive Relationship ◽  
Chronic Liver ◽  
Hemodynamic Parameters ◽  
Chronic Liver Diseases ◽  
Cerebral Hemodynamic

With cirrhosis of the liver statistically significant violations of cerebral hemodynamic parameters observed in intracranial department due to hemispheric asymmetry of blood flow. Hemispheric asymmetry of blood flow is marked by the development of vascular resistance and lability of the process of atherosclerosis. Hemispheric asymmetry between blood flow and stages of hepatic encephalopathy observed a noticeable positive relationship.

scholarly journals Cryptosporidiosis in patients with diarrhea and chronic liver diseases

2014 ◽  
Vol 8 (12) ◽  
pp. 1584-1590 ◽  
Author(s):  
Nasser Mousa ◽  
Ahmed Abdel-Razik ◽  
Hala El-Nahas ◽  
Atef El-Shazly ◽  
Mohammad Abdelaziz ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Liver Diseases ◽  
Meld Score ◽  
Chronic Liver ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cryptosporidium Infection ◽  
Chronic Liver Diseases ◽  
Pugh Class ◽  
Class C ◽  
Precipitating Factor

Introduction: The aim of this study was to evaluate the epidemiology and clinical significance of Cryptosporidium in patients with diarrhea and chronic liver diseases. Methodology: The study included 150 patients with chronic liver diseases and diarrhea, and 50 subjects with diarrhea as a control group. Stool samples were screened for the presence of Cryptosporidium by microscopic examination after modified Ziehl-Neelsen staining and detection of Cryptosporidium coproantigen by enzyme-linked immunosorbent assay (ELISA). Results: The prevalence of Cryptosporidium infection in patients with chronic liver diseases was 30% (45/150) versus 14% (7/50) in controls. Cryptosporidium infection increased with the progression of chronic liver diseases from Child-Pugh class A to Child-Pugh class C (p<  0.001) and from model for end-stage liver disease (MELD) score ≤ 9 to MELD score > 9 (p< 0.031). Nine patients in Child-Pugh class C with diarrhea associated with Cryptosporidium infection developed hepatic encephalopathy, and only diarrhea was identified as a precipitating factor for hepatic encephalopathy. Conclusions: Cryptosporidium is one of the important causes of diarrhea in patients with chronic liver diseases. The infection significantly increased with the progression of chronic liver diseases. In patients with advanced chronic liver diseases, Cryptosporidium infection may be a precipitating factor of hepatic encephalopathy.

scholarly journals Effect of histamine H2-receptor antagonists on the total hepatic blood flow in patients with chronic liver diseases.

Kanzo ◽  
1986 ◽  
Vol 27 (7) ◽  
pp. 908-914 ◽  
Author(s):  
Kouichi AKAMATSU ◽  
Souichiro MIYAUCHI ◽  
Kenya MURASE ◽  
Yuji WATANABE ◽  
Nobuo NISHIMURA ◽  
...  
Keyword(s):  
Blood Flow ◽  
Hepatic Blood Flow ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Receptor Antagonists ◽  
H2 Receptor Antagonists ◽  
Histamine H2 Receptor ◽  
H2 Receptor ◽  
Total Hepatic Blood Flow

A comparative study to determine the short-term mortality and clinical improvement in hepatic encephalopathy using either rifaximin and or lactulose

2021 ◽  
Vol 12 (3) ◽  
pp. 46-50
Author(s):  
Uttam Biswas ◽  
Shyamal Kanti Pal ◽  
Pallabi Ray Chaudhuri ◽  
Debanjan Roychowdhury ◽  
Abhranil Dhar ◽  
...  
Keyword(s):  
Hepatic Encephalopathy ◽  
Clinical Outcome ◽  
Clinical Improvement ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Precipitating Factors ◽  
Chronic Liver Diseases ◽  
Short Term ◽  
Significant Difference ◽  
Short Term Mortality

Background: Hepatic encephalopathy can be reversed by correcting precipitating factors and efficiently managed by lactulose and or rifaximin. Aims and Objective: The aim of this study to compare the effectiveness of three different modes of treatment in our study populations. Materials and Methods: Ninety patients of decompensated chronic liver diseases were selected and randomised to treat with either lactulose or rifaximin or both lactulose and rifaximin (30 patients in each group) for 7 days. Clinical outcome and short term mortality were noted in each group of treatment. This study was to review the comparison of the effectiveness of Rifaximin (1200mg/day , in 3 divided doses ) alone or in combination with Lactulose (60gram/day ,in divided doses) or Lactulose (60gram/day) alone to reduce the short term mortality and clinical improvement in hepatic encephalopathy of any grade of any cause in adult (>18 years) admitted patients of decompensated chronic liver diseases. Result: Clinical improvement was noted in all three modes of treatment but there is no statistically significant difference in clinical improvement of hepatic encephalopathy when compared amongst each of three modes of treatment. There was obvious reduction of short term mortality or clinical down gradation of hepatic encephalopathy grade after 7 days treatment using lactulose or rifaximin or combined lactulose and rifaximin but there was no statistically significant difference in this regard among these three modes of treatment. Conclusion: All three modes of treatment are equally effective though combination therapy is little better.

scholarly journals Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases

2021 ◽  
Vol 8 ◽  
Author(s):  
Liyuan Long ◽  
Hai Li ◽  
Guohong Deng ◽  
Xianbo Wang ◽  
Sihong Lu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Disease ◽  
Hepatic Encephalopathy ◽  
Liver Diseases ◽  
Clinical Characteristics ◽  
Adverse Outcomes ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Independent Risk Factors ◽  
Grade 3

Importance: Hepatic encephalopathy is a severe complication, and its contribution to clinical adverse outcomes in patients with acute-on-chronic liver diseases from the East is unclear.Objective: We aimed to investigate the impact of hepatic encephalopathy on clinical characteristics and adverse outcomes in prospective and multicenter cohorts of patients with acute-on-chronic liver diseases.Design: We conducted a cohort study of two multicenter prospective cohorts.Setting: China.Participants: Acute-on-chronic liver disease patients with various etiologies.Exposure: The diagnosis and severity of hepatic encephalopathy were assessed using the West Haven scale.Main Outcome Measure: The correlation between clinical adverse outcomes and varying hepatic encephalopathy grades was analyzed in the target patients.Results: A total of 3,949 patients were included, and 340 of them had hepatic encephalopathy. The incidence of hepatic encephalopathy was higher in patients with alcohol consumption (9.90%) than in those with hepatitis B virus infection (6.17%). The incidence of 28- and 90-day adverse outcomes increased progressively from hepatic encephalopathy grades 1–4. Logistic regression analysis revealed that hepatic encephalopathy grades 3 and 4 were independent risk factors for the 28- and 90-day adverse outcome in the fully adjusted model IV. Stratified analyses showed similar results in the different subgroups. Compared to grades 1–2 and patients without hepatic encephalopathy, those with grade 3 hepatic encephalopathy had a significant increase in clinical adverse outcomes, independent of other organ failures.Conclusions and Relevance: Hepatic encephalopathy grades 3–4 were independent risk factors for 28- and 90-day adverse outcomes. Hepatic encephalopathy grade 3 could be used as an indicator of brain failure in patients with acute-on-chronic liver disease.

Sign in / Sign up

Export Citation Format

Share Document